In recent years,
trehalose, a natural disaccharide, has attracted
growing attention because of the discovery of its potential to induce
autophagy. Trehalose has also been demonstrated to preserve the protein’s
structural integrity and to limit the aggregation of pathologically
misfolded proteins. Both of these properties have made trehalose a
promising therapeutic candidate to target autophagy-related disorders
and protein aggregation diseases. Unfortunately, trehalose has poor
bioavailability due to its hydrophilic nature and susceptibility to
enzymatic degradation. Recently, trehalose-bearing carriers, in which
trehalose is incorporated either by chemical conjugation or physical
entrapment, have emerged as an alternative option to free trehalose
to improve its efficacy, particularly for the treatment of neurodegenerative
diseases, atherosclerosis, nonalcoholic fatty liver disease (NAFLD),
and cancers. In the current Perspective, we discuss all existing literature
in this emerging field and try to identify key challenges for researchers
intending to develop trehalose-bearing carriers to stimulate autophagy
or inhibit protein aggregation.